Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- FDA Meeting Scheduled: The U.S. FDA has scheduled an advisory committee meeting on July 29 to discuss Capricor's (CAPR) marketing application for Deramiocel, a treatment for Duchenne muscular dystrophy, leading to a ~12% drop in stock price on Friday due to negative market sentiment.
- Application History: In July 2025, the FDA issued a complete response letter rejecting Capricor's Biologics License Application (BLA) for cardiomyopathy in DMD patients, indicating a cautious stance from regulators regarding the drug's approval.
- Resubmitted Application: Despite previous setbacks, the FDA accepted Capricor's resubmitted application in March, setting an action target date of August 22, which provides the company with another opportunity for approval, although market sentiment remains low.
- Industry Context: Similar to Capricor, Replimune (REPL) is facing FDA scrutiny for its lead drug RP1, which also faced rejections under previous FDA leadership, highlighting widespread regulatory challenges in the industry that may impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAPR
Wall Street analysts forecast CAPR stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.400
Low
45.00
Averages
51.57
High
60.00
Current: 30.400
Low
45.00
Averages
51.57
High
60.00
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Positive Five-Year Results for Deramiocel in DMD Study
- Durable Efficacy: In the HOPE-2 OLE study, patients treated with Deramiocel showed a mean total score decline of less than 5 points over five years, compared to a projected 12-point decline in standard care, indicating significant potential in slowing DMD progression.
- Stable Cardiac Function: The study demonstrated that left ventricular ejection fraction (LVEF) remained stable over five years, contrasting with an expected annual decline of approximately 3.2% in the comparator group, suggesting Deramiocel's effectiveness in preserving cardiac function and potentially reducing heart disease risk.
- Favorable Safety Profile: Throughout the clinical development program, Deramiocel maintained a favorable safety profile with over 800 intravenous infusions administered to date, with no new safety signals reported, enhancing its credibility as a treatment option for DMD.
- Regulatory Progress: Capricor is actively advancing its BLA application, with a target PDUFA date of August 22, 2026, which, if successful, could provide new treatment hope for DMD patients and further solidify the company's position in the biotechnology sector.
See More
Capricor's Biologics License Application Progress
- Advisory Committee Meeting Scheduled: The FDA plans to hold an Advisory Committee meeting on July 29, 2026, to discuss Capricor's Biologics License Application (BLA) for Deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy, marking a significant advancement in the company's efforts to address rare diseases.
- Clinical Trial Support: The BLA is backed by the long-term outcomes from the company's HOPE-2 trial and HOPE-2-OLE trial, while the HOPE-3 trial achieved statistical significance on its primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF), demonstrating the efficacy of Deramiocel.
- Significant Therapeutic Potential: As a first-in-class therapy, Deramiocel has shown clinically meaningful and statistically significant benefits in skeletal and cardiac functions across multiple studies, with a consistent safety profile, indicating its substantial potential in treating Duchenne muscular dystrophy.
- Regulatory Support and Market Outlook: Deramiocel has received Orphan Drug Designation from both the FDA and EMA, along with Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., highlighting its competitive edge and future approval potential, which may qualify Capricor for a Priority Review Voucher.
See More
Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting
- FDA Meeting Scheduled: The U.S. FDA has scheduled an advisory committee meeting on July 29 to discuss Capricor's (CAPR) marketing application for Deramiocel, a treatment for Duchenne muscular dystrophy, leading to a ~12% drop in stock price on Friday due to negative market sentiment.
- Application History: In July 2025, the FDA issued a complete response letter rejecting Capricor's Biologics License Application (BLA) for cardiomyopathy in DMD patients, indicating a cautious stance from regulators regarding the drug's approval.
- Resubmitted Application: Despite previous setbacks, the FDA accepted Capricor's resubmitted application in March, setting an action target date of August 22, which provides the company with another opportunity for approval, although market sentiment remains low.
- Industry Context: Similar to Capricor, Replimune (REPL) is facing FDA scrutiny for its lead drug RP1, which also faced rejections under previous FDA leadership, highlighting widespread regulatory challenges in the industry that may impact investor confidence.
See More
Caprock Mining Closes $600,000 Financing Through Flow-Through Shares
- Successful Financing: Caprock Mining Corp. has closed a non-brokered private placement of 6 million flow-through shares at $0.10 each, raising a total of $600,000, which will provide essential funding for the company's exploration projects.
- Clear Use of Proceeds: The funds raised will be allocated to eligible Canadian exploration expenses as defined under the Income Tax Act, specifically related to the Destiny gold project near Val d'Or, Québec, which is expected to drive further development of the project.
- Share Transfer Restrictions: The issued flow-through shares are subject to a four-month hold period expiring on October 20, 2026, ensuring stability post-financing and protecting investor interests.
- Significant Project Potential: The Destiny project is located within the Abitibi greenstone belt, comprising 127 mineral claims over an area of over 5,000 hectares, and has a published NI 43-101 compliant mineral resource estimate, highlighting its strategic value for future gold mining development.
See More
FDA Reversal Sparks Biotech Comeback for UniQure and Peers
- FDA Policy Reversal: The FDA's decision to reconsider UniQure's gene therapy candidate AMT-130, with plans to submit a U.S. marketing application in Q3 2026, signifies a potential accelerated approval for Huntington's disease treatment, which could create substantial market opportunities for the company.
- Regenxbio Stock Surge: Following the FDA announcement, Regenxbio's shares surged approximately 23%, positively impacting the future prospects of its gene therapy candidate RGX-121, despite the drug facing FDA rejection in February.
- Replimune's Recovery: Replimune's stock rose about 13%, as the company reached an agreement with the FDA to resubmit its Biologics License Application for RP1, aimed at providing a new treatment option for melanoma patients, demonstrating resilience in the face of adversity.
- Capricor's Continued Growth: Capricor Therapeutics saw its shares increase by around 8%, following the FDA's decision to review its previously rejected candidate Deramiocel for Duchenne muscular dystrophy, resulting in over a 130% rise in stock price over the past year, reflecting increased market confidence in its products.
See More
Capricor Sues Nippon Shinyaku Over DMD Therapy Distribution
- Legal Dispute Overview: In May, Capricor filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary NS Pharma over the distribution agreement for its DMD therapy Deramiocel, claiming that the current pricing structure could limit patient access through Medicare, Medicaid, and private insurance.
- Patient Access Challenges: Capricor highlighted that the existing agreement could lead to financial losses for hospitals and treatment centers administering the therapy, and despite attempts to resolve the issue with NS Pharma, no agreement was reached.
- FDA Review Progress: The PDUFA date for Deramiocel is set for August 22, 2026, with the FDA having resumed review of its Biologics License Application, indicating potential market approval to address the needs of approximately 15,000 DMD patients in the U.S.
- Market Sentiment Analysis: Retail sentiment around CAPR on Stocktwits trended bullish over the past 24 hours, accompanied by high message volumes, as investors focused on the potential impact of launching the drug independently, despite the stock shedding over 7% of its value this year.
See More
Positive Five-Year Results for Deramiocel in DMD Study
- Durable Efficacy: In the HOPE-2 OLE study, patients treated with Deramiocel showed a mean total score decline of less than 5 points over five years, compared to a projected 12-point decline in standard care, indicating significant potential in slowing DMD progression.
- Stable Cardiac Function: The study demonstrated that left ventricular ejection fraction (LVEF) remained stable over five years, contrasting with an expected annual decline of approximately 3.2% in the comparator group, suggesting Deramiocel's effectiveness in preserving cardiac function and potentially reducing heart disease risk.
- Favorable Safety Profile: Throughout the clinical development program, Deramiocel maintained a favorable safety profile with over 800 intravenous infusions administered to date, with no new safety signals reported, enhancing its credibility as a treatment option for DMD.
- Regulatory Progress: Capricor is actively advancing its BLA application, with a target PDUFA date of August 22, 2026, which, if successful, could provide new treatment hope for DMD patients and further solidify the company's position in the biotechnology sector.
See More
Capricor's Biologics License Application Progress
- Advisory Committee Meeting Scheduled: The FDA plans to hold an Advisory Committee meeting on July 29, 2026, to discuss Capricor's Biologics License Application (BLA) for Deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy, marking a significant advancement in the company's efforts to address rare diseases.
- Clinical Trial Support: The BLA is backed by the long-term outcomes from the company's HOPE-2 trial and HOPE-2-OLE trial, while the HOPE-3 trial achieved statistical significance on its primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF), demonstrating the efficacy of Deramiocel.
- Significant Therapeutic Potential: As a first-in-class therapy, Deramiocel has shown clinically meaningful and statistically significant benefits in skeletal and cardiac functions across multiple studies, with a consistent safety profile, indicating its substantial potential in treating Duchenne muscular dystrophy.
- Regulatory Support and Market Outlook: Deramiocel has received Orphan Drug Designation from both the FDA and EMA, along with Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., highlighting its competitive edge and future approval potential, which may qualify Capricor for a Priority Review Voucher.
See More
Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting
- FDA Meeting Scheduled: The U.S. FDA has scheduled an advisory committee meeting on July 29 to discuss Capricor's (CAPR) marketing application for Deramiocel, a treatment for Duchenne muscular dystrophy, leading to a ~12% drop in stock price on Friday due to negative market sentiment.
- Application History: In July 2025, the FDA issued a complete response letter rejecting Capricor's Biologics License Application (BLA) for cardiomyopathy in DMD patients, indicating a cautious stance from regulators regarding the drug's approval.
- Resubmitted Application: Despite previous setbacks, the FDA accepted Capricor's resubmitted application in March, setting an action target date of August 22, which provides the company with another opportunity for approval, although market sentiment remains low.
- Industry Context: Similar to Capricor, Replimune (REPL) is facing FDA scrutiny for its lead drug RP1, which also faced rejections under previous FDA leadership, highlighting widespread regulatory challenges in the industry that may impact investor confidence.
See More
Caprock Mining Closes $600,000 Financing Through Flow-Through Shares
- Successful Financing: Caprock Mining Corp. has closed a non-brokered private placement of 6 million flow-through shares at $0.10 each, raising a total of $600,000, which will provide essential funding for the company's exploration projects.
- Clear Use of Proceeds: The funds raised will be allocated to eligible Canadian exploration expenses as defined under the Income Tax Act, specifically related to the Destiny gold project near Val d'Or, Québec, which is expected to drive further development of the project.
- Share Transfer Restrictions: The issued flow-through shares are subject to a four-month hold period expiring on October 20, 2026, ensuring stability post-financing and protecting investor interests.
- Significant Project Potential: The Destiny project is located within the Abitibi greenstone belt, comprising 127 mineral claims over an area of over 5,000 hectares, and has a published NI 43-101 compliant mineral resource estimate, highlighting its strategic value for future gold mining development.
See More
FDA Reversal Sparks Biotech Comeback for UniQure and Peers
- FDA Policy Reversal: The FDA's decision to reconsider UniQure's gene therapy candidate AMT-130, with plans to submit a U.S. marketing application in Q3 2026, signifies a potential accelerated approval for Huntington's disease treatment, which could create substantial market opportunities for the company.
- Regenxbio Stock Surge: Following the FDA announcement, Regenxbio's shares surged approximately 23%, positively impacting the future prospects of its gene therapy candidate RGX-121, despite the drug facing FDA rejection in February.
- Replimune's Recovery: Replimune's stock rose about 13%, as the company reached an agreement with the FDA to resubmit its Biologics License Application for RP1, aimed at providing a new treatment option for melanoma patients, demonstrating resilience in the face of adversity.
- Capricor's Continued Growth: Capricor Therapeutics saw its shares increase by around 8%, following the FDA's decision to review its previously rejected candidate Deramiocel for Duchenne muscular dystrophy, resulting in over a 130% rise in stock price over the past year, reflecting increased market confidence in its products.
See More
Capricor Sues Nippon Shinyaku Over DMD Therapy Distribution
- Legal Dispute Overview: In May, Capricor filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary NS Pharma over the distribution agreement for its DMD therapy Deramiocel, claiming that the current pricing structure could limit patient access through Medicare, Medicaid, and private insurance.
- Patient Access Challenges: Capricor highlighted that the existing agreement could lead to financial losses for hospitals and treatment centers administering the therapy, and despite attempts to resolve the issue with NS Pharma, no agreement was reached.
- FDA Review Progress: The PDUFA date for Deramiocel is set for August 22, 2026, with the FDA having resumed review of its Biologics License Application, indicating potential market approval to address the needs of approximately 15,000 DMD patients in the U.S.
- Market Sentiment Analysis: Retail sentiment around CAPR on Stocktwits trended bullish over the past 24 hours, accompanied by high message volumes, as investors focused on the potential impact of launching the drug independently, despite the stock shedding over 7% of its value this year.
See More
